Ponholzer Anton, Stoiber Franz, Loidl Wolfgang, Rauchenwald Michael, Schramek Paul, Madersbacher Stephan
Abteilung für Urologie und Andrologie, Donauspital, SMZ-Ost, Wien, Austria.
Wien Med Wochenschr. 2009;159(21-22):515-20. doi: 10.1007/s10354-009-0718-0.
PSA is without any doubt the most frequently used marker in urology due to its helpful information regarding various aspects of diagnosis, therapy and prognosis in men with prostate cancer. On the other hand, many controversies still exist about the various indications for PSA-determination. The following overview is aimed to analyse the current status of PSA in the management of men undergoing screening, therapy or follow-up of prostate cancer. Anyhow, a detailed knowledge of how to use and interpret PSA and PSA-kinetics is considered to play a crucial role in prostate cancer patients. Current strategies are aimed to start and stop PSA-use earlier.
由于前列腺特异性抗原(PSA)在前列腺癌男性患者的诊断、治疗及预后等多方面能提供有用信息,它无疑是泌尿外科最常用的标志物。另一方面,关于PSA检测的各种适应证仍存在诸多争议。以下综述旨在分析PSA在前列腺癌筛查、治疗或随访男性患者管理中的现状。无论如何,深入了解如何使用和解读PSA及其动力学变化被认为在前列腺癌患者中起着关键作用。当前策略旨在更早地开始和停止使用PSA。